Related Experiment Videos
Helicobacter pylori eradication cost-benefit: the case against
1Digestive Diseases Research Centre, St Bartholomew's, London, UK.
British Medical Bulletin
|May 30, 1998
Summary
Helicobacter pylori (H. pylori) causes peptic ulcers and gastric cancer. Eradicating H. pylori offers clear clinical and economic benefits for peptic ulcer disease, but its value in asymptomatic carriers requires further examination.
Area of Science:
- Gastroenterology
- Infectious Diseases
- Microbiology
Background:
- Helicobacter pylori is a significant human pathogen.
- It is linked to peptic ulcer disease, gastric cancer, and other conditions.
- H. pylori infection is common, but most infected individuals remain asymptomatic.
Purpose of the Study:
- To evaluate the clinical and economic benefits of H. pylori eradication.
- To specifically examine the advantages of eradication in asymptomatic carriers.
Main Methods:
- Literature review on H. pylori pathogenesis and treatment efficacy.
- Analysis of clinical outcomes and healthcare costs associated with H. pylori infection.
- Economic modeling to assess the cost-effectiveness of eradication strategies.
Main Results:
- H. pylori eradication is clinically and economically justified for peptic ulcer disease.
- The majority of H. pylori-infected individuals do not develop overt disease.
- The benefit of eradication in asymptomatic carriers warrants careful consideration.
Conclusions:
- H. pylori eradication is a key strategy for managing peptic ulcer disease.
- Further research is needed to determine the optimal approach for H. pylori management in asymptomatic populations.
- Balancing the benefits and costs of H. pylori eradication is crucial for public health.